Valeant Pharmaceuticals (BHC) - Company Value to Net Income

Corporate emblem and logo of Bausch Health Companies Inc. (BHC)

R&D restructuring and debt are hindering innovation in gastroenterology for Bausch Health Companies (BHC). The company's historical P/E illustrates the asset's resilience to market shocks, while -3.70 captures the magnitude of this parameter. The business foundation relies on ophthalmology and GI solutions for B2B/B2C segments. Diversification through cosmetology and pharmacy chains ensures the stability of the holding's revenues.

BHC bauschhealth.com: Price to Earnings Ratio in the range 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Valeant Pharmaceuticals (BHC)

- share price and expert price forecast:
Price Performance Chart bauschhealth.com|BHC - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Bausch Health Companies Inc.|BHC - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Bausch Health|BHC - Company Book Value|Market Value to Book Value Ratio bauschhealth.com|BHC - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Ratio Bausch Health Companies|BHC - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Bausch Health Corp|BHC - Company Debts|Debt to Book Value Ratio Bausch Health Companies Inc.|BHC - Company Long-Term Debts|Short-Term Indebtedness Bausch Health|Quick Liquidity bauschhealth.com
- business earnings and investment ratios data:
BHC - Net Profit|Projected Future Earnings Bausch Health Companies|BHC - Price to Earnings Ratio|Forward P/E Multiple Bausch Health Companies Inc.|BHC - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Bausch Health Companies Inc.|BHC - Operating profit EBITDA|Net earnings per share for the last 12 months Bausch Health|BHC - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months bauschhealth.com|BHC - Net earnings per share growth this year|Expected earnings per share trend next year Bausch Health Companies
Comprehensive company analysis:bauschhealth.com BHC
Product sample of Bausch Health Companies

Stable capacity utilization of pharmaceutical facilities at Bausch Health Companies (BHC) provides the foundation for valuing the business via the price-to-earnings ratio. By analyzing the company's median P/E, an investor determines the investment payback period and the degree of asset overvaluation, which, combined with equipment modernization, confirms the operational resilience and long-term attractiveness of the securities.

Key competitors

LLY: Company Value to Net Income|P/E Multiple ABBV|AZN (AstraZeneca Plc) - Company Value to Net Income|Price to Earnings Ratio Novartis Inc. NVS|MSD (MRK) - Market Cap to Earnings|NVO - Price to Earnings Ratio|AMGN: Price to Earnings Ratio|PFE: P/E Multiple|Price to Earnings Multiple SNY|BMY (BMS) - P/E Multiple|GSK Corp (GSK) - Business Payback Period|Price to Earnings Ratio Takeda Pharmaceutical (TAK)|Teva Pharmaceuticals - Price to Earnings Multiple|P/E Multiple RDY (Dr. Reddy's)|Market Cap to Net Income Ratio Viatris Inc|Roivant Sciences Ltd - P/E Multiple|ZLAB: Price to Earnings Ratio|COSM: P/E Multiple